Cigna-Express Scripts merger delayed

Amy Baxter | | Health Exec | Policy & Regulations

The completion of the $67 billion merger between health insurer Cigna and Express Scripts has been delayed, according to a public filing. The deal was anticipated to close by December 8, but the companies have decided to delay that deadline by six months.

Both companies expect the transactions by the merger agreement will close in 2018, however, the filing states. Cigna has received approvals for a change of control of an insurer from all but three states––California, New York and New Jersey. Certain state insurance regulators have the authority to approve the change of control of an insurer.

The new merger deadline is June 8, 2018. The deal was approved by the Department of Justice in September.

The merger, which brings together a major pharmacy benefits manager and a health insurance and services provider, is one of the largest in the healthcare space. The cost of the transaction topped $200 million as of September.

Another significant merger, CVS Health’s $69 billion acquisition of Aetna, is expected to close Nov. 28.

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

A modest proposal to rally AI regulators around a simple game plan
FDA set to ban certain over-the-counter cold medications
FDA commissioner urges clinicians to join fight against medical misinformation
Looming fear of more IV shortages as Hurricane Rafael gains strength
Walgreens settles class-action fraud lawsuit for $100M
Boston Medical Center installs solar panels to pay patients’ electric bills

Around the web

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Design by Adaptive Theme
Trimed Popup
Trimed Popup